# the Efficacy and Safety of Ginsenoside Rg3 Capsule in Prevention of Postoperative Recurrence of Hepatocellular Carcinoma

> **NCT01717066** · NA · COMPLETED · sponsor: **ShenFeng** · enrollment: 480 (actual)

## Conditions studied

- Stage I Hepatocellular Carcinoma
- Stage II Hepatocellular Carcinoma

## Interventions

- **DRUG:** the ginsenoside Rg3
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01717066
- **Lead sponsor:** ShenFeng
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-04
- **Primary completion:** 2014-12
- **Final completion:** 2015-05
- **Target enrollment:** 480 (ACTUAL)
- **Last updated:** 2016-03-31

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01717066

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01717066, "the Efficacy and Safety of Ginsenoside Rg3 Capsule in Prevention of Postoperative Recurrence of Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01717066. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*